Comparative Pharmacology
Head-to-head clinical analysis: INREBIC versus TOFACITINIB CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INREBIC versus TOFACITINIB CITRATE.
INREBIC vs TOFACITINIB CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fedratinib is a selective Janus kinase 2 (JAK2) inhibitor. It inhibits JAK2 and its mutant forms, including JAK2V617F, leading to reduced phosphorylation of signal transducer and activator of transcription (STAT) proteins and decreased proliferation of abnormal hematopoietic cells.
Janus kinase (JAK) inhibitor; inhibits JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), thereby modulating cytokine signaling and downregulating immune and inflammatory responses.
100 mg orally twice daily continuously until disease progression or unacceptable toxicity.
5 mg orally twice daily for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis; 10 mg orally twice daily for ulcerative colitis induction (8 weeks maximum).
None Documented
None Documented
Terminal elimination half-life approximately 14 hours; supports twice-daily dosing for steady-state attainment within 3 days
Terminal elimination half-life is approximately 3 hours (range 2–4 hours) in patients with normal renal function, allowing twice-daily dosing. Half-life is prolonged in moderate to severe renal impairment (up to 5–8 hours) and in hepatic impairment.
Fecal (77.6% as metabolites, 2.2% as unchanged drug); renal (8.5% as metabolites, <1% as unchanged drug)
Approximately 70% of the dose is eliminated by hepatic metabolism, with about 30% excreted unchanged in urine and <10% in feces. Renal excretion accounts for ~30% of total clearance.
Category C
Category D/X
JAK Inhibitor
JAK Inhibitor